172 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
7:14am
Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties
8-K
EX-99.1
6u8lulnvfupdyc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-99.1
jta hi1uz
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
zk44 rr1tqev
31 Jan 24
Other Events
5:07pm
8-K
EX-99.1
0kjl55v 57mk4bpy4
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
EX-99.1
75knnv8vzn92ykpwnu3
6 Dec 23
Other Events
7:13am
8-K
EX-99.1
93r0c1fk9j7u2dz
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
nfja9szb6alx5dqi
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
p68yi
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.1
wdkzj0is
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
dc41hin3p5g
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm